Kornimate/medical-research-clean huggingface dataset:
target gene sequencing for advanced stage, relapsed or refractory natural killer/t-cell lymphoma

Conditions: Lymphoid Neoplasm

Summary: although modern radiation techniques combined with chemotherapy has greatly improved the local control and long-term survivals for patients with early-stage nktcl, relapse and systemic dissemination are common for localized patients. relapsed/refractory diseases together with advanced stage nktcls uaually progress rapidly with poor prognosis (5-year overall survival rate, 0-20%). according to published studies, some recurrent genetic alternations have been identified in nktcl, including oncogene/tumor suppressive gene abberants, epigenetic changes, cellular signaling pathways abnormalities, cellular apoptosis related genes and so forth. however, the gene profiling techniques and materials vary in different studies, no consensus has been reached on the gene abnormalities of advanced, or relapsed/refractory nktcl up to now. additionally, gene sequencing using ctdna of peripheral blood has been unexploited in nktcl patients.


Eligibility criteria:
inclusion criteria: 1. diagnosis of nktcl with typical morphology and immunophenotype, according to the 2008 world health organization classification of lymphomas; 2. stage iii/iv disease; or relapsed or refractory disease after at least one line prior teratment; 3. age ≥ 18 years; 4. ecog performance status 0-2; 5. at least one measurable lesion; 6. adequate hematological, hepatic, and renal functions; 7. life expectancy of more than 3 months. exclusion criteria: 1. previously untreated stage i/ii disease; 2. with no adequate tumour tissue; 3. any coexisting medical problems of sufficient severity to prevent full compliance with the study protocol.
ruxolitinib for polycythemia vera in patients resistant to or intolerant of hydroxyurea.

Conditions: Polycythemia Vera (PV)

Summary: this was an analytical and descriptive, non-interventional, retrospective cohort study of pv patients aged ≥ 18 years in the us using a secondary data source, optum ehr database.

the optum ehr database was current up to 30-jun-2020. identification period: from 01-apr-2007 to 30-jun-2019 study period: from 01-jan-2007 to 30-jun-2020 index date: first evidence of resistance to or intolerance of hu treatment in patients with pv according to modified european leukemia net (eln) criteria and defined as: 1. hct ≥ 45% with phlebotomy (last phlebotomy within last 3 months) or 2. platelet count \> 400 x 109/l and presence of palpable splenomegaly (palpable spleen up to 3 months after platelet count) pre-index period: patients had a minimum of 3 months pre-index data available. pre-index data availability was determined using the reported 'first month active' field. post-index period: there was no minimum post-index period required. each patient had a 'first month active' and 'last month active' reported within the database. as the 'last month active' was based on any activity in the database, including encounters such as letters and emails which occurred several months after the 'death_date' of the patient, using the 'last month active' can overestimate the follow-up for a given patient. for this reason, the end of follow-up for each patient was defined as the date of the last activity within the diagnosis, observations, prescriptions, laboratories, procedures tables or discharge date from the last visit within the visit table (whichever of these activities occurs latest). this underestimated the follow-up for some patients where they were not actively using healthcare resources.

Eligibility criteria:
inclusion criteria: included patients: * with at least one international classification of diseases, 9th revision, clinical modification/international classification of diseases,10th revision, clinical modification code for pv in the identification period (01-apr-2007 until 30-jun-2019) that had non-missing sex and year of birth data and who were treated as part of the integrated delivery network * that were ≥ 18 years old at pv diagnosis * with ≥ 2 prescriptions of hu * that were classified as resistant to or intolerant of hu after a minimum of 3 months hu treatment (index date), defined as: hct ≥ 45% with phlebotomy (last phlebotomy within last 3 months) or platelet count \> 400 x 109/l and presence of palpable splenomegaly (palpable spleen up to 3 months after platelet count). to identify patients in the rux group: - with ≥ 2 prescriptions of rux in the post-index period. exclusion criteria: excluded patients: - with a mf or aml diagnosis prior to a pv diagnosis.

Keywords: polycythemia vera, ruxolitinib, jak protein inhibitor, hydroxyurea, thrombotic events
effectiveness of rebif® in clinically isolated syndrome and relapsing multiple sclerosis using rebismart™

Conditions: Relapsing Multiple Sclerosis; Clinically Isolated Syndrome

Summary: this is a phase 4, interventional, multicenter study of subcutaneous rebif® (interferon beta-1a) using rebismart™ device to assess effectiveness and adherence of treatment in subjects with clinically isolated syndrome (cis) or relapsing multiple sclerosis (rms).


Eligibility criteria:
inclusion criteria: * male and female subjects between 18 to 65 years of age * female subjects must be neither pregnant nor breast-feeding and must lack child-bearing potential as defined in the protocol * subjects diagnosed with cis or rms according to the revised mcdonald criteria (2010) * treatment-naive subjects or subjects treated with rebif® multi-dose injected by rebismart™ for no longer than 6 weeks prior to baseline visit * subjects that are able to self-inject with rebismart™ (in the opinion of the physician) * subjects with expanded disability status scale (edss) score less than (\<) 6 (inclusive) at baseline * signed informed consent and subject data collection form exclusion criteria: * subjects experiencing a relapse within 30 days before baseline * participation in other studies within 30 days before baseline * received any ms therapy within 6 months prior to study enrolment (for example, other disease-modifying drugs: immunomodulatory, immunosuppressive agents or combination therapy) with the exception of rebif® multi-dose injected by rebismart™ * any visual or physical impairment that precludes the subject from self-injecting the treatment using the rebismart™ * pregnancy and breast-feeding * serious or acute heart disease such as uncontrolled cardiac dysrhythmias, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure, as per investigator opinion * current or past (within the last 2 years) history of alcohol or drug abuse * have any contra-indications to treatment with interferon beta-1a according to summary of product characteristics

Keywords: relapsing multiple sclerosis clinically isolated syndrome rms cis rebismart™ rebif® interferon beta-1a
the effect of aromatherapy for first dental visit patients

Conditions: Dental Anxiety

Summary: first dental visit experience is strongly correlated with dental anxiety, the aim of this protocol is to explore the efficacy of olfactory aromatherapy for the reduce of dental anxiety and pain in first-visit patient.


Eligibility criteria:
inclusion criteria: * patients who never visited dental clinics before; * patients who need dental treatment, such as resin filling, root canal treatment, periodontal initial treatment, tooth extraction, etc; * patients and their guardians who are able to understand the purpose of the study and volunteer to take part in the study; * patients who are intellectually sufficient to complete the anxiety scale; * be able to complete all assessments and follow-up during the study. exclusion criteria: * patients who are allergic to the ingredients of the essential oils used in the experiment or to the materials used in the dental treatment; * patients who underwent only an oral examination; * patients with severe heart disease, hypertension, respiratory disease, or other systemic conditions that were not eligible for trial participation; * pregnant or lactating women; * people with depressive symptoms, anxiety disorders or other mental illnesses that affect their mood state; * people who are using sedative or analgesic drugs; * recent or current users of essential oils; * any circumstances considered by the investigator to be inappropriate for participation in this study.

Keywords: dental anxiety aromatherapy first dental visit
context-awareness, physiological monitoring, and machine learning in migraine and cluster headache

Conditions: Migraine; Cluster Headache

Summary: this is an observational, longitudinal cohort pilot study measuring physiological signals through wearable sensors combined with machine learning algorithms to detect behaviour, stress and headaches in patients with migraine and cluster headache.

migraine and cluster headache are among the most disabling headache conditions in humans. both conditions have different phases such as the prodromal/premonitory phase, the aura phase, the headache phase and the postdromal phase. this pilot study examines the potential of wearable sensors combined with machine learning algorithms to investigate the biological changes over time in both conditions. behaviour such as movement, sleep and activity will be monitored. stress levels will be estimated through the wearable data combined with input from the patients. participants will use a wearable device around the wrist and self-developed headache application for 21 days.

Eligibility criteria:
inclusion criteria: * migraine or cluster headache diagnosis based on ichd 3 criteria * at least 2 attacks each month * onset of headache syndrome before the age of 50 * if multiple headache syndromes coexist: attacks are clearly distinguishable * participant has smartphone that he/she wants to apply for this research exclusion criteria: * chronic migraine patients * history of alcohol or illicit drug abuse * significant medical comorbidity deemed by the investigator to interfere with the study * use of betablockers * participating in other academic or commercial trials
evaluation of ave5026 as compared to placebo for the extended prophylaxis of venous thromboembolism in patients having undergone hip fracture surgery

Conditions: Venous Thromboembolism

Summary: the primary objective is to evaluate the efficacy of once daily (qd) subcutaneous (sc) injections of semuloparin sodium (ave5026) versus placebo for 3 additional weeks following an initial 7 to 10-day venous thromboprophylaxis with open-label ave5026 in patients having undergone hip fracture surgery. the secondary objective is to evaluate the safety of extended ave5026 administration.

the total duration of observation per participant is 56-63 days from surgery broken down as follows: * 7 to 10-day initial treatment period with open-label semuloparin sodium; * randomization; * 19 to 23-day double-blind treatment period with semuloparin sodium or placebo; * 30-day follow-up period. mandatory bilateral venography of the lower limbs is to be performed between 19 and 24 days after randomization.

Eligibility criteria:
inclusion criteria: * in the run-in phase: * standard surgery for fracture of the upper third of the femur, including femoral head and neck * in the double-blind phase following the run-in phase: * completion of the run-in phase without permanent treatment discontinuation exclusion criteria: * any major orthopedic surgery within 3 months prior to enrolment; * deep vein thrombosis or pulmonary embolism within the last 12 months, or known post-phlebitic syndrome; * high risk of bleeding; * known hypersensitivity to heparins; * any contraindication to the performance of venography; * end stage renal disease or patient on dialysis the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: venous thromboprophylaxis primary prevention orthopedic surgery
anti-inflammatory milk matrix

Conditions: Obesity; Skeletal Muscle; Inflammation

Summary: obesity is pro-inflammatory, impairs metabolism, and physically limiting. specifically, muscle in obese persons does not synthesize proteins normally. this further increases metabolic and physical dysfunction. as such, obesity programs should not only focus on weight loss, but muscle metabolic health. dairy nutrients have anti-inflammatory and anabolic properties, but mostly evaluated in isolation and/or pre-clinical designs. also, it is unknown if the circulating benefits extend to the muscle. we hypothesize that dairy full-fat milk will improve these obesity characteristics.


Eligibility criteria:
inclusion criteria: * obese (bmi, body mass index ≥30, \<40 kg•m-2) * age 40-59 * pre-menopausal * sedentary/insufficiently active for prior 6 months (mo) * weight stable for prior 6 mo exclusion criteria: * tobacco, nicotine (patch/gum) use (previous 6 mo) * alcohol consumption \>10 drinks per week * metabolic disorders (e.g., metabolic syndrome, diabetes, thyroid diseases) * cardiovascular disease, arrhythmias * hypogonadism * asthma * history of uncontrolled hypertension * orthopedic injury/surgery (within 1 yr) * hepatorenal, musculoskeletal, autoimmune, or neurological disease * history of neuromuscular problems * previous participation in amino acid tracer studies * predisposition to hypertrophic scarring or keloid formation * consumption of ergogenic-levels of dietary supplements that may affect muscle mass (e.g., creatine, hmb), insulin-like substances, or anabolic/catabolic pro-hormones (e.g., dhea) within 6 weeks prior to participation * consumption of thyroid, androgenic, or other medications known to affect endocrine function * consumption of medications known to affect protein metabolism (e.g., prescription-strength corticosteroids, non-steroidal anti-inflammatories, or acne medication) * pregnancy * allergy to dairy product or lactose intolerance * fasting plasma glucose (fpg) ≥ 126 mg/dl * oral glucose tolerance test (ogtt) ≥ 200 mg/dl
elective neurectomy during inguinal hernia repair

Conditions: Inguinal Hernia

Summary: chronic inguinal neuralgia is one of the most important complications following inguinal hernia repair. it may even outweigh the benefit of the operation. intraoperative neurectomy has been investigated to reduce the incidence of chronic pain. this study evaluates the effects of elective division of the ilioinguinal, iliohypogastric and genital branch of the genitofemoral nerves on pain and postoperative sensory symptoms after lichtenstein hernia repair.


Eligibility criteria:
inclusion criteria: * uni- or bilateral inguinal hernia * karnofsky-index ≥70 * informed consent exclusion criteria: * recurrent inguinal hernia * previous inguinal operation * emergent operation * severe comorbidities

Keywords: inguinal hernia chronic pain neurectomy hypesthesia
nutrition, immunology and epidemiology of tuberculosis

Conditions: Tuberculosis

Summary: the purpose of this study is to determine the efficacy of micronutrient supplementation among patients with active tuberculosis, half of who are co-infected with hiv-1

tuberculosis (tb) remains the single most common infectious disease cause of mortality. we propose to examine the inter- relationships of nutrition, immunology, and epidemiology with respect to tb in tanzania. given that tb is so much linked with hiv immunologically, clinically, and epidemiologically, it is essential to examine how these relationships are modified by hiv infection. published animal and human studies suggest that vitamin deficiency is associated with poor immune response in tb. by modulating immune function, nutritional supplements may be a useful adjunct to anti-tb drugs, and could lead to the development of shorter drug regimens. all patients will receive standard anti-tb therapy. follow-up visits will occur every two weeks for the first 2 months and monthly thereafter till the end of the study.

Eligibility criteria:
inclusion criteria: * men and women, age 18 to 60 years inclusive * at least two positive sputum smears for tuberculosis * intention to stay in dar-es-salaam for at least 2 years after the start of tb therapy * subjects who grant informed consent to participation exclusion criteria: * karnofsky score \< 40% * hemoglobin \< 8.5 g/dl * having had treatment for tb exceeding 4 weeks in the last 5 years * pregnant women

Keywords: tuberculosis hiv tanzania multivitamins
evaluation of the effects of silk and polyester suture on postoperative complications

Conditions: Impacted Third Molar Tooth

Summary: some undesirable complications such as pain, swelling, trismus, paresthesia, hematoma, infection and, albeit rare, fractures may occur after lower impacted wisdom tooth surgery. more effective wound closure methods with fewer complications have positive effects on postoperative recovery. suturing is the most commonly used wound closure technique after lower impacted wisdom tooth surgery. suturing, which is the last step of the operation, contributes to wound healing in order to reposition and stabilize the tissue components and to control bleeding. in our study, it was aimed to evaluate the efficacy of silk and polyester sutures used in wound closure techniques, which are frequently used in lower impacted wisdom teeth surgery.

this randomized, single-blind, split-mouth study was carried out on 30 patients who applied to van yuzuncu yıl university, faculty of dentistry, department of oral, dental and maxillofacial surgery. silk suture was used on one side of the patients and polyester suture was used on the other side. when the patients first applied to the clinic, their anamnesis was taken and panoramic images were taken after clinical evaluations were made. evaluations were made with preoperative face measurements (for evaluation of swelling), maximum mouth opening (for evaluation of trismus) and periodontal measurements for all patients. the mentioned measurements and evaluations were repeated on the 2nd and 7th postoperative days. in addition, postoperative pain was evaluated with the vas scale. the same surgical procedure was performed by the same surgeon for all patients. after local anesthesia (2ml of 80 mg articaine hydrochloride + 0.02mg epinephrine bitartrate) a 3-corner flap containing the vertical incision passing through the mesial of the number 7 was lifted, the bone removed under saline cooling and the teeth were separated when needed. afterwards, the extraction sockets will be irrigated with saline to control bleeding, and the area is closed primarily with silk or polyester suture material.

Eligibility criteria:
inclusion criteria: * individuals aged 18 years and over * impacted teeth in mesial and horizontal positions and in class 2 and class b according to pell \& gregory classification, * asymptomatic impacted teeth, * individuals who is coming to control and fill in the given and requested forms, * individuals with an operation time of 30 minutes or less exclusion criteria: * systemic disease, * smoking, * pregnancy or breastfeeding, * allergy to the drugs to be used in the study, * using any additional medication that may affect the outcome of the study, * using medication until 2 weeks before the operations, * post-operative alveolitis.
reassure spot respiration rate accuracy compared to somnoscreen

Conditions: Accuracy of Measurement of Respiration Rate

Summary: a trial conducted within the company with a new non-contact respiration rate (rr) sensor. the device was compared for accuracy in rr measurement with a cleared device, the somnoscreen easy, which uses chest effort bands. the rr was measured over a short duration on subjects sitting upright in a chair, with the non-contact sensor at various distances from the subject. a total of 20 subjects were tested, from both genders, selected to represent a wide range of age and body mass index

the reassure uses radio frequency (rf) waves to detect the small movements of the human body due to respiration. the reference device, the somnoscreen, uses chest effort bands. the reassure is non-contact and so more comfortable and convenient for quick rr measurement, in a similar way that an infra-red thermometer is compared to a traditional under-the-tongue mercury thermometer. the aim is to explore the variations in the human body that could have an effect on the radio reflection from the human torso, and thus affect the potential detection and accuracy of breathing rate. factors that could affect non-contact rf performance are: * high body mass index (bmi) could potentially reduce the chest wall movement during breathing, or alter the nature of the breathing. * elderly, thin skin (ie pensioner with low bmi) may have less rf reflection. * female breast tissue may have an effect on detection or accuracy. this was tested at a number of distances from the non-contact sensor and also with the subject having a thick comforter (duvet) laid across them. the test conditions were * distances of 0.5 m, 1.0m and 1.5m between the subject and the rf sensor. * additional test condition of comforter (duvet) on the subject when the distance from subject to sensor is 1.0 m. * each test condition carried out twice. the use of the comforter in one test condition is to confirm that the rr measurement by the reassure is unaffected by the thickness of clothing or blankets being worn.

Eligibility criteria:
inclusion criteria: * greater or equal to 18 years old and less than or equal to 75 years old * bmi within the range of greater or equal to 18 and less than or equal to 45

Keywords: respiration rate
the effects of walnuts, walnut-oil, almonds and fish oils on glucose homeostasis in polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome; Insulin Resistance

Summary: the purpose of this study is to learn more about the effects of walnuts, walnut-oil, almonds and fish oils on blood sugar and insulin levels in polycystic ovary syndrome (pcos) patients. the hypothesis is that a diet rich in these foods will improve insulin resistance in women with pcos.

polycystic ovary syndrome is a common disease that affects 1 out of 16 women. metabolic and endocrine abnormalities seen in pcos include insulin resistance, androgen excess and infertility. this study focuses on the insulin resistance aspect because increased insulin resistance leads to premature onset of impaired glucose tolerance or diabetes whereas decreased insulin resistance reduces androgen excess, improves the ovarian function and increases fertility. although insulin resistance can be treated with insulin-sensitizing drugs, pcos clinically manifests during adolescence and the long-term safety of the drug-treatment can be a concern. thus, improving insulin resistance with effective nutritional approaches would be very desirable. epidemiological studies and animal experiments suggest that replacement of dietary saturated fats with monounsaturated (mufa) and polyunsaturated (pufa) fats improves insulin resistance.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of polycystic ovary syndrome * body mass index (bmi) 22-52 exclusion criteria: * habitual dietary intake of less than 30% fat * use of oral contraceptives, insulin sensitizers, d-chiro inositol, or any other supplements affecting weight or insulin sensitivity during the preceding two months * impaired glucose tolerance * diabetes mellitus * other system illnesses such as renal, hepatic, gastrointestinal, severe hyperlipidemia and hypertension that require medication * smoking, alcohol intake (more than 2 drinks/week) * the laboratory values used for exclusion of subjects will be fasting glucose \> 110 mg/dl, glycosylated hemoglobin (hgba1) \> 6.5%, serum creatinine \> 1.5 mg/dl, alt or ast \> 2x the upper limit of normal, cholesterol \> 250 mg/dl. the investigators will also exclude subjects with hematocrit \< 30%.

Keywords: pcos polycystic ovary syndrome insulin resistance fish oil walnut-oil walnuts almonds monounsaturated fats polyunsaturated fats mufa pufa